Augmedix (AUGX) 10-Q 12 Aug 24 2024 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 07, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-40890
Entity Registrant Name	AUGMEDIX, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-3299164
Entity Address, Address Line One	111 Sutter Street
Entity Address, Address Line Two	Suite 1300
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94104
City Area Code	(888)
Local Phone Number	669-4885
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	AUGX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		49,243,752
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001769804
Document Fiscal Year Focus	2024

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 28,220	$ 46,217
Restricted cash	0	125
Accounts receivable, net of allowance for credit losses of $204 and $110 at June 30, 2024 and December 31, 2023, respectively	9,252	8,572
Prepaid expenses and other current assets	2,453	1,909
Total current assets	39,925	56,823
Property and equipment, net	3,333	3,739
Operating lease right of use asset	4,431	5,220
Restricted cash, non-current	5,207	0
Deposits and other assets	776	930
Total assets	53,672	66,712
Current liabilities:
Accounts payable	881	721
Accrued expenses and other current liabilities	6,929	6,589
Deferred revenue	8,902	8,963
Customer deposits	851	851
Operating lease liability, current portion	1,432	1,494
Loan payable, current portion	5,000	5,000
Total current liabilities	23,995	23,618
Operating lease liability, net of current portion	3,303	4,049
Loan payable, net of current portion	15,540	15,303
Other liabilities	360	421
Total liabilities	43,198	43,391
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized; 49,080,486 and 48,613,714 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	171,480	169,197
Accumulated deficit	(159,911)	(144,962)
Accumulated other comprehensive loss	(1,100)	(919)
Total stockholders' equity	10,474	23,321
Total liabilities and stockholders' equity	$ 53,672	$ 66,712

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts receivable, allowance for credit losses	$ 204	$ 110
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	49,080,486	48,613,714
Common stock, shares outstanding (in shares)	49,080,486	48,613,714

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenues	$ 13,664	$ 10,780	$ 27,136	$ 20,408
Cost of revenues	7,209	5,715	14,340	10,957
Gross profit	6,455	5,065	12,796	9,451
Operating expenses:
General and administrative	7,013	4,760	12,360	8,967
Sales and marketing	3,749	2,649	7,313	5,212
Research and development	4,418	2,590	8,250	5,300
Total operating expenses	15,180	9,999	27,923	19,479
Loss from operations	(8,725)	(4,934)	(15,127)	(10,028)
Other income (expense):
Interest expense	(639)	(558)	(1,255)	(966)
Interest income	410	276	913	438
Change in fair value of warrant liability	0	(69)	0	(69)
Other	590	303	527	437
Total other income (expense), net	361	(48)	185	(160)
Net loss before income taxes	(8,364)	(4,982)	(14,942)	(10,188)
Income tax expense	86	51	7	84
Net loss	(8,450)	(5,033)	(14,949)	(10,272)
Other comprehensive income (loss):
Foreign exchange translation adjustment	(194)	(298)	(181)	(331)
Total comprehensive loss	$ (8,644)	$ (5,331)	$ (15,130)	$ (10,603)
Net loss per share of common stock, basic (in dollars per share)	$ (0.16)	$ (0.12)	$ (0.28)	$ (0.25)
Net loss per share of common stock, diluted (in dollars per share)	$ (0.16)	$ (0.12)	$ (0.28)	$ (0.25)
Weighted average shares of common stock outstanding, basic (in shares)	53,387,349	43,607,984	53,223,008	40,566,425
Weighted average shares of common stock outstanding, diluted (in shares)	53,387,349	43,607,984	53,223,008	40,566,425

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2022		37,442,663
Beginning Balance at Dec. 31, 2022	$ 1,466	$ 4	$ 127,693	$ (125,791)	$ (440)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)		112,252
Exercise of common stock options	85		85
Share-based compensation expense	533		533
Foreign currency translation adjustment	(33)				(33)
Net loss	(5,239)			(5,239)
Ending Balance (in shares) at Mar. 31, 2023		37,554,915
Ending Balance at Mar. 31, 2023	(3,188)	$ 4	128,311	(131,030)	(473)
Beginning Balance (in shares) at Dec. 31, 2022		37,442,663
Beginning Balance at Dec. 31, 2022	1,466	$ 4	127,693	(125,791)	(440)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(10,272)
Ending Balance (in shares) at Jun. 30, 2023		40,800,078
Ending Balance at Jun. 30, 2023	3,989	$ 4	140,819	(136,063)	(771)
Beginning Balance (in shares) at Mar. 31, 2023		37,554,915
Beginning Balance at Mar. 31, 2023	(3,188)	$ 4	128,311	(131,030)	(473)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and warrants, net of issuance costs (in shares)		3,125,000
Issuance of common stock and warrants, net of issuance costs	11,845		11,845
Exercise of common stock options (in shares)		82,121
Exercise of common stock options	93		93
Exercise of common stock warrants (in shares)		38,042
Share-based compensation expense	570		570
Foreign currency translation adjustment	(298)				(298)
Net loss	(5,033)			(5,033)
Ending Balance (in shares) at Jun. 30, 2023		40,800,078
Ending Balance at Jun. 30, 2023	$ 3,989	$ 4	140,819	(136,063)	(771)
Beginning Balance (in shares) at Dec. 31, 2023	48,613,714	48,613,714
Beginning Balance at Dec. 31, 2023	$ 23,321	$ 5	169,197	(144,962)	(919)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)		62,535
Exercise of common stock options	59		59
Exercise of common stock warrants (in shares)		94,804
Share-based compensation expense	885		885
Foreign currency translation adjustment	13				13
Net loss	(6,499)			(6,499)
Ending Balance (in shares) at Mar. 31, 2024		48,771,053
Ending Balance at Mar. 31, 2024	$ 17,779	$ 5	170,141	(151,461)	(906)
Beginning Balance (in shares) at Dec. 31, 2023	48,613,714	48,613,714
Beginning Balance at Dec. 31, 2023	$ 23,321	$ 5	169,197	(144,962)	(919)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (14,949)
Ending Balance (in shares) at Jun. 30, 2024	49,080,486	49,080,486
Ending Balance at Jun. 30, 2024	$ 10,474	$ 5	171,480	(159,911)	(1,100)
Beginning Balance (in shares) at Mar. 31, 2024		48,771,053
Beginning Balance at Mar. 31, 2024	17,779	$ 5	170,141	(151,461)	(906)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)		210,533
Exercise of common stock options	154		154
Issuance of common stock for settlement of restricted stock units and stock awards (in shares)		98,900
Share-based compensation expense	1,152		1,152
Change in fair value of the warrant	33		33
Foreign currency translation adjustment	(194)				(194)
Net loss	$ (8,450)			(8,450)
Ending Balance (in shares) at Jun. 30, 2024	49,080,486	49,080,486
Ending Balance at Jun. 30, 2024	$ 10,474	$ 5	$ 171,480	$ (159,911)	$ (1,100)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (14,949)	$ (10,272)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	855	541
Share-based compensation	2,037	1,098
Non-cash interest expense	390	255
Loss on disposal of property and equipment	49	0
Change in fair value of warrant liability	0	69
Non-cash lease expenses	601	437
Provision for bad debt	188	26
Changes in operating assets and liabilities:
Accounts receivable	(868)	(3,105)
Prepaid expenses and other current assets	(549)	(250)
Deposits and other assets	81	(442)
Accounts payable	399	(102)
Accrued expenses and other liabilities	399	(567)
Deferred revenue	(61)	604
Customer deposits	0	(38)
Lease liability	(617)	(429)
Net cash used in operating activities	(12,045)	(12,175)
Cash flows from investing activities:
Purchase of property and equipment	(930)	(1,475)
Proceeds from the sale of property and equipment	27	0
Net cash used in investing activities	(903)	(1,475)
Cash flows from financing activities:
Proceeds from loan payable	0	5,000
Payment of financing costs	(80)	(55)
Proceeds from issuance of common stock and warrants, net of issuance costs	0	11,845
Proceeds from exercise of stock options	213	179
Net cash provided by financing activities	133	16,969
Effect of exchange rate changes on cash and restricted cash	(100)	(47)
Net decrease in cash, cash equivalents and restricted cash	(12,915)	3,272
Cash, cash equivalents and restricted cash at beginning of period	46,342	21,988
Cash, cash equivalents and restricted cash at end of period	33,427	25,260
Supplemental disclosure of cash flow information:
Cash paid for interest	864	667
Cash paid for income taxes	56	8
Cash paid for operating lease liabilities	716	485
Supplemental schedule of non-cash investing and financing activities:
Purchases of property and equipment in accounts payable	289	155
Operating lease right-of-use asset exchanged for operating lease liability	0	2,498
Fair value of warrants issued in connection with loan	0	492
Change in fair value of warrants in connection with loan amendment	33	0
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	28,220	24,551
Restricted cash	0	125
Restricted cash, non-current	5,207	584
Total cash, cash equivalents and restricted cash	$ 33,427	$ 25,260

Organization and Basis of Prese

Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Augmedix, Inc. (the “Company”, “we” or “our”) was incorporated in 2013 and launched its commercial real-time, remote documentation services in 2014. The Company delivers ambient artificial intelligence (AI) medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine clinicians. Clinicians access our applications through mobile devices. The Company is headquartered in San Francisco, CA, with offices in three (3) countries around the world. Liquidity The Company has historically funded its operations primarily by debt and equity financings, and revenue earned from our customers. In April of 2023, the Company raised $11.8 million in net proceeds after direct financing costs of $191 thousand, from the issuance of 3,125,000 shares of common stock, a warrant to purchase 4,375,273 shares of common stock at an exercise price of $0.0001 per share, and a warrant to purchase 1,875,069 common stock at an exercise price of $1.75 per share. Additionally, in November of 2023, the Company issued 7,187,500 shares of common stock and raised net proceeds of $26.3 million, after underwriter's commissions and direct financing costs of $2.5 million. As of June 30, 2024, the Company’s existing sources of liquidity included cash and cash equivalents of $28.2 million plus up to $5.0 million in incremental capital available through the SVB Loan Agreement (as defined below). The Company has incurred negative cash flows from operating activities and losses from operations in the past as reflected in the accumulated deficit of $159.9 million as of June 30, 2024. We expect losses and negative cash flows to continue, primarily as a result of continued research, development and marketing efforts. We believe our cash balance will provide sufficient resources to meet our working capital needs for over twelve months from the filing date of the Form 10-Q for the three and six months ended June 30, 2024 . Over the longer term, if we do not generate sufficient revenue from new and existing products, we may have to obtain additional debt or equity financing and reduce expenditures. There is no assurance that if we require additional future financing that such financing will be available on terms which are acceptable to us, or at all. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission, (“SEC”), for interim reporting. Certain information and note disclosures included in the Company’s annual financial statements have been condensed or omitted pursuant to such rules and regulations. The accompanying unaudited interim condensed consolidated financial statements include the accounts of Augmedix, Inc. and its wholly-owned subsidiaries, Augmedix Operating Corporation, Augmedix Bangladesh Limited, and Augmedix Solutions Private Limited. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature considered necessary for a fair presentation of the Company's consolidated financial position, results of operations, comprehensive loss, and cash flows for the interim periods presented. The interim results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2024. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 26, 2024. Risks and Uncertainties The Company is subject to a number of risks associated with companies at a similar stage with international operations, including dependence on key personnel, competition from similar products and larger companies, ongoing changes within the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company, the ability to manage international operations including changes in regulations, and general economic conditions, including economic volatility caused by the uncertain direction of interest rates. Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments relate to the incremental borrowing rate used to measure operating lease liabilities and right of use assets, and stock-based compensation, including expected volatility used to measure the fair value of stock options and stock appreciation rights. Actual results could differ from those estimates.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company’s significant accounting policies are discussed in “Consolidated Financial Statements — Note 2. Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. There have been no significant changes to these policies during the three months ended June 30, 2024, except for updated information related to the accounting policies below. Restricted Cash Restricted cash represents amounts held on deposit at a commercial bank used to secure the Company’s credit card facility. This facility was closed in the second quarter of 2024. Restricted cash, non-current as of June 30, 2024, represents a cash deposit that collateralizes the term loan as more fully described in note 6 - Debt, and a letter of credit in the name of the Company’s landlord pursuant to a certain operating lease. Government Grant Income From time to time, the Company may receive grant income from the Bangladesh Government related to our operations in Bangladesh. The Company records this grant income when received and the grants are recorded in the other category of other income (expense), net on the condensed consolidated statement of operations. The Company recorded grant income of $431 thousand and $78 thousand during the three months ended June 30, 2024 and 2023, respectively, and $431 thousand and $78 thousand during the six months ended June 30, 2024 and 2023. Advertising Costs All advertising costs are expensed as incurred and included in sales and marketing expenses. Advertising expenses incurred by the Company were $319 thousand and $210 thousand for the three months ended June 30, 2024 and 2023, respectively and $583 thousand and $428 thousand for the six months ended June 30, 2024 and 2023. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”) . The amendments expand segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, the amount and description of other segment items, permits companies to disclose more than one measure of segment profit or loss, and requires all annual segment disclosures to be included in the interim periods. The amendments do not change how an entity identifies its operating segments, aggregates those operating segments, or applies quantitative thresholds to determine its reportable segments. The amendments are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on the consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”) , which modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on the consolidated financial statements and related disclosures.

Revenue, Accounts Receivable an

Revenue, Accounts Receivable and Significant Customers	6 Months Ended
	Jun. 30, 2024
Revenue From Contract With Customer, Accounts Receivable, And Concentration Risk [Abstract]
Revenue, Accounts Receivable and Significant Customers	Revenue, Accounts Receivable and Significant Customers The Company derives nearly all of its revenue through a recurring subscription model. The Company enters into contracts with its customers that typically have an initial term of one year. Most customers are invoiced in advance and must generally pay an upfront implementation fee. The upfront implementation fee is deferred and recognized over the initial contract term and any customer prepayments are deferred and included in the accompanying consolidated balance sheets in deferred revenue. Revenues are recognized over time as we provide our services to our customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Changes in the contract liability, which solely includes deferred revenue, were as follows: Six Months Ended June 30, 2024 Year Ended December 31, 2023 Balance, beginning of period $ 8,963 $ 7,254 Deferral of revenue 23,687 42,846 Recognition of unearned revenue (23,748) (41,137) Balance, end of period $ 8,902 $ 8,963 Deferred revenues consist of billings or payments received in advance of revenue recognized for the Company’s services, as described above, and are recognized as revenue when earned. The Company has an unconditional right to payment under a non-cancellable contract before it transfers services to its customer. The Company’s accounts receivable are derived from contracts with customers located in the U.S. Significant customers generating more than 10% of the Company's revenue during the period indicated or for which accounts receivable balance was more than 10% of the total accounts receivable balance were as follows: Percent of Revenue for Three Months Ended June 30, Percent of Revenue for Six Months Ended June 30, 2024 2023 2024 2023 Customer A 30 % 21 % 30 % 19 % Customer B 11 % 14 % 11 % 14 % Customer C 10 % 12 % 10 % 12 % Percent of Accounts Receivable June 30, 2024 December 31, 2023 Customer A 33 % 35 % Customer C n/a n/a Customer D n/a 10 % Customer E n/a n/a The Company capitalizes sales commissions incurred to obtain a revenue contract and amortizes such costs over 12 to 24 months . The Company amortized $171 thousand and $215 thousand of sales commissions in sales and marketing expense during the three months ended June 30, 2024 and 2023, respectively, and $308 thousand and $372 thousand during the six months ended June 30, 2024 and 2023.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: June 30, December 31, Computer hardware, software and equipment $ 4,809 $ 4,730 Leasehold improvements 915 716 Capitalized internal-use software costs 712 698 Furniture and fixtures 607 693 Construction in progress 10 393 7,054 7,230 Less: accumulated depreciation (3,720) (3,491) Property and equipment, net $ 3,333 $ 3,739 Depreciation expense was $416 thousand and $262 thousand during the three months ended June 30, 2024 and 2023, respectively, and $855 thousand and $541 thousand during the six months ended June 30, 2024 and 2023, respectively. The Company recorded a gain on disposal of leasehold improvements and equipment of $6 thousand during the three months ended June 30, 2024 and a loss on disposal of leasehold improvements of $49 thousand during the six months ended June 30, 2024. There were no gains or losses on the disposals of property and equipment during the three and six months ended June 30, 2023. Gains and losses on disposals of property and equipment are presented in other income (loss) on the condensed consolidated statement of operations and comprehensive loss.

Accrued expenses and other curr

Accrued expenses and other current liabilities	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities Accrued expenses and other current liabilities consists of the following: June 30, December 31, Accrued compensation $ 2,440 $ 3,860 Accrued professional fees 1,570 138 Accrued vendor partner liabilities 1,290 1,285 Accrued indirect taxes 336 393 Revenue refund reserve 199 198 Accrued interest payable 142 146 Accrued other 952 569 $ 6,929 $ 6,589

Debt

Debt	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Debt	Debt On May 4, 2022 (the “Effective Date”), the Company and its subsidiary (individually and collectively, “Borrower”) entered into a loan and security agreement (the “SVB Loan Agreement”) with Silicon Valley Bank, a California corporation, as lender (“SVB”). The SVB Loan Agreement provides the Borrower with a revolving credit facility in an aggregate principal amount of the lesser of (i) $5.0 million or (ii) 80% of eligible accounts (the “Revolving Credit Facility”) and two tranches of term loan advances, comprised of a term loan advance under Tranche A in an aggregate principal amount of up to $15.0 million and additional term loan advances under Tranche B in an aggregate principal amount of up to $5.0 million (the “Term Loan Facility” and, together with the Revolving Credit Facility, the “Facilities”). Borrower’s obligations under the SVB Loan Agreement are secured by first-priority liens on substantially all assets of Borrower. On June 12, 2023, the Borrower entered into a First Amendment to Loan and Security Agreement (“Amendment”) with SVB, which amends certain provisions of the SVB Loan Agreement. Under the Amendment, the Term Loan Facility’s initial stated maturity date of June 1, 2025 was extended to December 1, 2025. The Amendment provides for further automatic extensions of the Term Loan Facility’s maturity date, with the possibility of automatic extension to June 1, 2027, if the Company achieves certain equity milestones as set forth in the Amendment and certain performance milestones with respect to revenue and net income (loss) as set forth in the Amendment. The Amendment also extended the stated maturity date of the Revolving Credit Facility from May 4, 2024 to November 4, 2024. Interest on the borrowings under the Term Loan Facility is payable at a floating rate per annum equal to the greater of (a) 6.00% and (b) the prime rate plus 0%, and interest on borrowings under the Revolving Credit Facility is payable at a floating rate per annum equal to the greater of (a) 6.50% and (b) the prime rate plus 0.50%. If the Company prepays the Term Loan Facility before maturity, the Company will incur a prepayment fee, which depends on when the balance is prepaid. The prepayment fee equals 2.50%, 1.50%, and 0.50% of the outstanding principal amount of the Term Loan Facility, if the prepayment occurs during the first, second or third year following of the effective date of the amendment of June 12, 2023, respectively. There is no prepayment fee if the Term Loan Facility is replaced with another facility with the SVB. In connection with the SVB Loan Agreement and Amendment, on May 4, 2022, the Company issued to SVB a warrant to purchase up to 48,295 shares of the Company’s common stock at an exercise price of $2.38 per share. Additionally, on June 13, 2023, the Company issued to SVB a warrant to purchase up to 190,330 shares of the Company’s common stock at an exercise price of $3.01 per share. Both of these warrants expire seven years after the issuance date. On June 26, 2024 the Borrower entered into a Second Amendment to Loan and Security Agreement ("Second Amendment"). The Second Amendment of the Term Loan Facility extended the maturity to December 1, 2026 and extended the interest only period applicable to the Term Loan Facility until January 1, 2025. The Second Amendment also provides that the interest only period of the Term Loan Facility may be extended to July 1, 2025 and that the maturity date for the revolving credit facility may be extended to November 4, 2025, in SVB's sole and absolute discretion. Additionally, the Second Amendment requires the Company to maintain $5 million in a cash collateral account maintained with the SVB and pledged in favor of the SVB. Further, in connection with the Second Amendment, the Company reduced the exercise price of the warrants to purchase up to 190,330 shares of common stock issued on June 13, 2023 from $3.01 per share to $1.09 per share. The SVB Loan Agreement contains customary restrictions and covenants applicable to Borrower and its subsidiaries. In particular, the SVB Loan Agreement contains a financial covenant that provides that if Borrower fails to maintain minimum cash and cash equivalents in an amount of (a) no less than $25.0 million (prior to any Tranche B advance) and (b) $30.0 million (following any Tranche B advance), Borrower is then required to maintain certain minimum revenue requirements as set forth in the SVB Loan Agreement, which will be measured on a trailing three-month basis and tested quarterly. If Borrower has failed to maintain the minimum cash and cash equivalents set forth in the preceding sentence, in lieu of being subject to the minimum revenue requirements, Borrower has the ability to cure such failure to maintain minimum cash and cash equivalents by delivering evidence satisfactory to SVB that Borrower has raised at least $10.0 million in net cash proceeds from the sale of Borrower’s equity interests. As of June 30, 2024, the future minimum payments required under the SVB Loan Agreement, including the final payment, are as follows as: 2024 (6 months remaining) $ — 2025 10,000 2026 11,225 $ 21,225 Less: unamortized debt discount (685) Loan payable net of discount $ 20,540 Less: current portion (5,000) Loan payable, non-current portion $ 15,540 The Term Loan Facility includes an end of term payment of $1.2 million, which has been recorded as both a discount and an increase to the principal amount of the debt. The debt discount is being amortized to interest expense over the remaining term of the Term Loan Facility which matures on December 1, 2026 using the effective interest method. The Company amortized $151 thousand and $126 thousand of the discount to interest expense during the three months ended June 30, 2024 and 2023, respectively, and $300 thousand and $225 thousand during the six months ended June 30, 2024 and 2023, respectively.

Leases

Leases	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Leases	Leases The Company leases office facilities in San Francisco, California, Bangladesh, and India. Lease costs for the periods indicated below are as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating lease cost $ 406 $ 336 $ 816 $ 546 Short-term lease cost 15 91 68 175 Total lease cost $ 421 $ 427 $ 884 $ 721 The weighted average remaining term and weighted average discount rate for the Company's operating leases are as follows: June 30, 2024 December 31, 2023 Weighted-average remaining lease term (in years) 3.5 4.0 Weighted-average discount rate 8.3 % 8.3 % As of June 30, 2024, the maturities of the Company’s operating lease liabilities (excluding short-term leases) are as follows: 2024 (remaining six months) $ 686 2025 1,636 2026 1,695 2027 1,021 2028 459 2029 10 Total $ 5,507 Less: imputed interest (773) Operating lease liability 4,734 Less: Operating lease liability, current portion 1,432 Operating lease liability, net of current portion $ 3,303

Common Stock Warrants

Common Stock Warrants	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Common Stock Warrants	Common Stock Warrants At June 30, 2024, the Company had the following warrants outstanding to acquire shares of its common stock: Expiration Date Shares Exercise October 25, 2024 346,500 $ 3.00 June 11, 2025 234 $ 96.24 November 13, 2025 84,964 $ 3.00 July 28, 2027 91 $ 106.17 August 28, 2028 1,052 $ 39.76 May 4, 2029 48,295 $ 4.00 September 2, 2029 1,556,732 $ 2.88 April 19, 2030 1,875,069 $ 1.75 June 13, 2030 190,330 $ 1.09 Perpetual 4,375,273 $ 0.0001 8,478,540 The perpetual common stock warrants in the table above are included in the weighted average shares outstanding for purpose of calculating loss per share since the issuance date of April 19, 2023 given the nominal exercise price, but are not considered outstanding common shares as of June 30, 2024 or December 31, 2023.

Loss Per Share

Loss Per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Loss Per Share	Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of common stock outstanding during each period. Diluted net loss per common stock includes the effect, if any, from the potential exercise or conversion of securities, such as options and warrants which would result in the issuance of incremental common stock. In computing basic and diluted net loss per share, the weighted average number of shares is the same for both calculations due to the fact that a net loss existed for the three and six months ended months ended June 30, 2024 and 2023. The Company calculated basic and diluted net loss per share as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Numerator Net Loss $(8,450) $(5,033) $(14,949) $(10,272) Denominator Weighted average shares, basic and diluted 53,387,349 43,607,984 53,223,008 40,566,425 Net loss per share $(0.16) $(0.12) $(0.28) $(0.25) The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: June 30, June 30, Common stock warrants 4,103,267 4,743,466 Stock options and stock appreciation rights 9,136,058 9,562,621 Restricted stock units 2,069,018 263,155 15,308,343 14,569,242

Equity Incentive Plan

Equity Incentive Plan	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plan	Equity Incentive Plan The Company grants share-based payment awards to employees, non-employee directors and service providers of the Company under the Augmedix, Inc. 2020 Equity Incentive Plan (“2020 Plan”). The 2020 Plan authorizes the award of stock options, restricted stock awards ("RSAs"), stock appreciation rights ("SARs"), restricted stock units ("RSUs"), performance awards, cash awards, and stock awards. Certain awards provide for accelerated vesting in the event of a change in control. Options issued may have a contractual life of up to 10 years and may be exercisable in cash or as otherwise determined by the Board of Directors. Vesting generally occurs over a period of not greater than four years. The number of shares of common stock reserved for issuance under the 2020 Plan increased on January 1, 2021, and will increase each anniversary thereafter through 2030 by the number of shares of common stock equal to the lesser of 5% of the total number of outstanding shares of common stock as of the immediately preceding January 1, or a number as may be determined by the Company’s board of directors. As of June 30, 2024, there were 812,032 shares of common stock that remained available for grant under the 2020 Plan. Share-based compensation expense in the following expense categories in the condensed consolidated statements of operations and comprehensive loss was as follows for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 General and administrative $ 670 $ 381 $ 1,206 $ 738 Sales and marketing 193 64 325 123 Research and development 244 93 418 184 Cost of revenues 46 27 87 53 Total share-based compensation $ 1,152 $ 565 $ 2,037 $ 1,098 No income tax benefits have been recognized in the condensed consolidated statements of operations and comprehensive loss for stock-based compensation arrangements. Stock Options and Stock Appreciation Rights The grant date fair value of stock options and stock appreciation rights was estimated using a Black-Scholes option pricing model with the following weighted average assumptions: Six Months Ended June 30, 2024 2023 Expected term (in years) 5.9 5.9 Expected volatility 61.8 % 54.4 % Risk-free rate 4.4 % 1.9 % Dividend rate — — The weighted average grant date fair value of stock option awards and SARs granted was $2.33 and $1.13 for the six months ended June 30, 2024 and 2023, respectively. The following table summarizes stock option and SARs activity for the six months ended June 30, 2024: Number of Weighted- Weighted- Outstanding at December 31, 2023 9,342,589 $ 1.94 7.2 Granted 169,550 $ 3.92 Exercised (278,808) $ 0.88 Forfeited and expired (97,273) $ 3.59 Outstanding at June 30, 2024 9,136,058 $ 2.00 6.7 Exercisable at June 30, 2024 6,486,698 $ 1.74 6.2 Vested and expected to vest at June 30, 2024 9,136,058 $ 2.00 6.7 The intrinsic value of the options exercised during the six months ended June 30, 2024 was $863 thousand. The aggregate intrinsic value of options outstanding and options exercisable as of June 30, 2024 was $0.4 million and $0.4 million, respectively. At June 30, 2024, future stock-based compensation for options and SARs outstanding of $2.5 million will be recognized over a remaining weighted-average requisite service period of 2.2 years. Restricted Stock Units The following table summarizes RSU activity for the six months ended June 30, 2024: Number of Weighted Outstanding at December 31, 2023 303,688 $ 4.91 Granted 1,906,800 $ 3.94 Vested (111,783) $ 3.91 Forfeited and expired (29,687) $ 4.39 Outstanding at June 30, 2024 2,069,018 $ 4.08 The aggregate intrinsic value of RSUs outstanding as of June 30, 2024, was $1.8 million. At June 30, 2024, future stock-based compensation for RSUs granted and outstanding of $7.9 million will be recognized over a remaining weighted-average requisite service period of 3.6 years. Performance and Market-Based Options As more fully described in “Consolidated Financial Statements — Note 10. Equity Incentive Plans” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, in March 2021, the Company granted 727,922 stock options to the Company’s Chief Executive Officer (“CEO”) under the 2020 Plan with an exercise price of $3.00 per share. These options vest based on the CEO’s continued service in addition the Company's stock price reaching the following thresholds for a minimum of 20 out of 30 trading days before the option expiration dates: Tranche Number of Option Shares Stock Price Threshold Option Expiration 1 317,688 $9.00 March 3, 2031 2 46,273 $9.00 March 21, 2031 3 363,961 $13.50 March 21, 2031 Total 727,922

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2024
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans The Company maintains a 401(k) plan that covers substantially all U.S. based employees and to which the Company provides a matching contribution equal to 25% of an employee's contribution up to the first 4% of the employee's eligible compensation. The matching contribution vests after 1 year of service. The Company match expense for was $67 thousand and $38 thousand during the three months ended June 30, 2024 and 2023, respectively, and $126 thousand and $90 thousand during the six months ended June 30, 2024 and 2023, respectively. For employees in Bangladesh and India, the Company provides post-employment benefit plans as required by local requirements. Under these plans, employees are entitled to receive a cash benefit upon leaving the Company after completion of a minimum of five years of service with the Company. The cash benefit is based on the number of years the employee has worked for the Company. The expense for these benefit plans was $107 thousand and $77 thousand during the three months ended June 30, 2024 and 2023, respectively, and $234 thousand and $201 thousand during the six months ended June 30, 2024 and 2023, respectively. The Company has accrued an aggregate of $361 thousand and $421 thousand in other liabilities in the accompanying condensed consolidated balance sheet as of June 30, 2024 and December 31, 2023, respectively for these benefit plans.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Cloud Computing Services In May 2024, the Company entered into a non-cancelable five-year contract to obtain cloud computing services that replaced a prior three-year contract entered into in June 2021. The purchase commitment over the five-year period is $5.3 million and includes three commitment periods with the following commitment amounts: Commitment Period Commitment Period Commitment Amount 1 June 2024 to May 2026 $1,740 2 June 2026 to May 2028 2,265 3 June 2028 to May 2029 1,311 Total commitment $5,316 Under this contract, if the actual amount spent during any commitment period is less than the respective commitment amount, then the Company will be required to pay such deficit and such payment cannot be recovered by spending more than the commitment amount in a subsequent commitment period. Any amounts spent during a commitment period in excess of the respective commitment amount will carry over to the subsequent commitment period and count toward that period's commitment amount. As of June 30, 2024, the Company has spent $56 thousand against this contract. Legal In the normal course of business, the Company may receive inquiries or become involved in legal disputes regarding various litigation matters. As of June 30, 2024 and December 31, 2023, there were no legal contingency matters, either individually or in aggregate, that would have a material adverse effect on the Company’s financial position, results of operations, or cash flows. Given the unpredictable nature of legal proceedings, the Company bases its assessment on the information available at the time. As additional information becomes available, the Company reassesses the potential liability and may revise the estimate. No liability related to such matters has been recorded at June 30, 2024 or December 31, 2023. Indemnification Agreements In the normal course of business, the Company may indemnify other parties when it enters into contractual relationships, including members of the Company’s board of directors, employees, customers, lessors and parties to other transactions with the Company. The Company may agree to hold other parties harmless against specific losses, such as those that could arise from a breach of representation, covenant, or third-party infringement claims. It may not be possible to determine the maximum potential amount of liability under such indemnification agreements due to the unique facts and circumstances that are likely to be involved in each particular claim and indemnification provision. As a result, no liability for these agreements has been recorded at June 30, 2024 or December 31, 2023.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amounts of cash, cash equivalents, restricted cash, accounts receivable, prepaid expenses, accounts payable, and customer deposits approximate fair value due to their short-term nature. The following tables present information about our financial instruments that have been measured at fair value as of June 30, 2024 and December 31, 2023: June 30, (Level 1) (Level 2) (Level 3) Financial Assets Money market funds $ 25,339 $ 25,339 $ — $ — Total $ 25,339 $ 25,339 $ — $ — Financial Liabilities Loan payable $ 20,540 $ — $ — $ 20,540 Total $ 20,540 $ — $ — $ 20,540 December 31, (Level 1) (Level 2) (Level 3) Financial Assets Money market funds $ 43,104 $ 43,104 $ — $ — Total $ 43,104 $ 43,104 $ — $ — Financial Liabilities Loan payable $ 20,303 $ — $ — $ 20,303 Total $ 20,303 $ — $ — $ 20,303

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Operating Leases In 2015, the Company entered into agreements to rent office facilities in Bangladesh under 10-year operating lease agreements (Note 7), with a company owned by relatives of Ian Shakil, the Company's Chief Strategy Officer and a member of the Company's Board. The Company incurred rent expense to this related party of $0 thousand and $101 thousand during the three months ended June 30, 2024 and 2023, respectively, and $70 thousand and $195 thousand during the six months ended June 30, 2024 and 2023, respectively. The amount owed to this related party at June 30, 2024 and December 31, 2023 was $2 thousand and $8 thousand, respectively, and are included in accounts payable in the accompanying consolidated balance sheet. These lease agreements were terminated in the first quarter of 2024.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event Plan of Merger with Commure, Inc. On July 19, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Commure, Inc., a Delaware corporation (“Parent”), and Anderson Merger Sub, Inc., a Delaware corporation and direct wholly-owned subsidiary of Parent (“Merger Sub”). The Merger Agreement provides that, subject to the terms and conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Company (the “Merger”), with the Company continuing as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each issued and outstanding share of the Company’s common stock, par value $0.0001 per share (“Company Common Stock”), will be cancelled and extinguished and automatically converted into the right to receive cash in an amount equal to $2.35, without interest (the “Per Share Price”), and subject to applicable tax withholding. The Merger Agreement contains customary covenants made by each of the Company, Parent and Merger Sub, including, among others, covenants by the Company regarding the conduct of its business prior to the closing of the Merger. Consummation of the Merger is subject to the satisfaction or waiver of customary closing conditions, including adoption of the Merger Agreement by the Company’s stockholders.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net loss	$ (8,450)	$ (6,499)	$ (5,033)	$ (5,239)	$ (14,949)	$ (10,272)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission, (“SEC”), for interim reporting. Certain information and note disclosures included in the Company’s annual financial statements have been condensed or omitted pursuant to such rules and regulations. The accompanying unaudited interim condensed consolidated financial statements include the accounts of Augmedix, Inc. and its wholly-owned subsidiaries, Augmedix Operating Corporation, Augmedix Bangladesh Limited, and Augmedix Solutions Private Limited. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments relate to the incremental borrowing rate used to measure operating lease liabilities and right of use assets, and stock-based compensation, including expected volatility used to measure the fair value of stock options and stock appreciation rights. Actual results could differ from those estimates.
Restricted Cash	Restricted Cash Restricted cash represents amounts held on deposit at a commercial bank used to secure the Company’s credit card facility. This facility was closed in the second quarter of 2024. Restricted cash, non-current as of June 30, 2024, represents a cash deposit that collateralizes the term loan as more fully described in note 6 - Debt, and a letter of credit in the name of the Company’s landlord pursuant to a certain operating lease.
Government Grant Income	Government Grant Income
Advertising Costs	Advertising Costs
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”) . The amendments expand segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, the amount and description of other segment items, permits companies to disclose more than one measure of segment profit or loss, and requires all annual segment disclosures to be included in the interim periods. The amendments do not change how an entity identifies its operating segments, aggregates those operating segments, or applies quantitative thresholds to determine its reportable segments. The amendments are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on the consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”) , which modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on the consolidated financial statements and related disclosures.

Revenue, Accounts Receivable _2

Revenue, Accounts Receivable and Significant Customers (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue From Contract With Customer, Accounts Receivable, And Concentration Risk [Abstract]
Schedule of changes in contract liability	Changes in the contract liability, which solely includes deferred revenue, were as follows: Six Months Ended June 30, 2024 Year Ended December 31, 2023 Balance, beginning of period $ 8,963 $ 7,254 Deferral of revenue 23,687 42,846 Recognition of unearned revenue (23,748) (41,137) Balance, end of period $ 8,902 $ 8,963
Schedule of concentration of risk	The Company’s accounts receivable are derived from contracts with customers located in the U.S. Significant customers generating more than 10% of the Company's revenue during the period indicated or for which accounts receivable balance was more than 10% of the total accounts receivable balance were as follows: Percent of Revenue for Three Months Ended June 30, Percent of Revenue for Six Months Ended June 30, 2024 2023 2024 2023 Customer A 30 % 21 % 30 % 19 % Customer B 11 % 14 % 11 % 14 % Customer C 10 % 12 % 10 % 12 % Percent of Accounts Receivable June 30, 2024 December 31, 2023 Customer A 33 % 35 % Customer C n/a n/a Customer D n/a 10 % Customer E n/a n/a

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment consist of the following: June 30, December 31, Computer hardware, software and equipment $ 4,809 $ 4,730 Leasehold improvements 915 716 Capitalized internal-use software costs 712 698 Furniture and fixtures 607 693 Construction in progress 10 393 7,054 7,230 Less: accumulated depreciation (3,720) (3,491) Property and equipment, net $ 3,333 $ 3,739

Accrued expenses and other cu_2

Accrued expenses and other current liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consists of the following: June 30, December 31, Accrued compensation $ 2,440 $ 3,860 Accrued professional fees 1,570 138 Accrued vendor partner liabilities 1,290 1,285 Accrued indirect taxes 336 393 Revenue refund reserve 199 198 Accrued interest payable 142 146 Accrued other 952 569 $ 6,929 $ 6,589

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of future minimum payments required	As of June 30, 2024, the future minimum payments required under the SVB Loan Agreement, including the final payment, are as follows as: 2024 (6 months remaining) $ — 2025 10,000 2026 11,225 $ 21,225 Less: unamortized debt discount (685) Loan payable net of discount $ 20,540 Less: current portion (5,000) Loan payable, non-current portion $ 15,540

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Schedule of lease costs	Lease costs for the periods indicated below are as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating lease cost $ 406 $ 336 $ 816 $ 546 Short-term lease cost 15 91 68 175 Total lease cost $ 421 $ 427 $ 884 $ 721
Schedule of other lease information	The weighted average remaining term and weighted average discount rate for the Company's operating leases are as follows: June 30, 2024 December 31, 2023 Weighted-average remaining lease term (in years) 3.5 4.0 Weighted-average discount rate 8.3 % 8.3 %
Schedule of operating lease maturities	As of June 30, 2024, the maturities of the Company’s operating lease liabilities (excluding short-term leases) are as follows: 2024 (remaining six months) $ 686 2025 1,636 2026 1,695 2027 1,021 2028 459 2029 10 Total $ 5,507 Less: imputed interest (773) Operating lease liability 4,734 Less: Operating lease liability, current portion 1,432 Operating lease liability, net of current portion $ 3,303

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Schedule of warrants outstanding to acquire shares of common stock	At June 30, 2024, the Company had the following warrants outstanding to acquire shares of its common stock: Expiration Date Shares Exercise October 25, 2024 346,500 $ 3.00 June 11, 2025 234 $ 96.24 November 13, 2025 84,964 $ 3.00 July 28, 2027 91 $ 106.17 August 28, 2028 1,052 $ 39.76 May 4, 2029 48,295 $ 4.00 September 2, 2029 1,556,732 $ 2.88 April 19, 2030 1,875,069 $ 1.75 June 13, 2030 190,330 $ 1.09 Perpetual 4,375,273 $ 0.0001 8,478,540

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per share	The Company calculated basic and diluted net loss per share as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Numerator Net Loss $(8,450) $(5,033) $(14,949) $(10,272) Denominator Weighted average shares, basic and diluted 53,387,349 43,607,984 53,223,008 40,566,425 Net loss per share $(0.16) $(0.12) $(0.28) $(0.25)
Schedule of antidilutive securities excluded from computation of diluted weighted-average shares	The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: June 30, June 30, Common stock warrants 4,103,267 4,743,466 Stock options and stock appreciation rights 9,136,058 9,562,621 Restricted stock units 2,069,018 263,155 15,308,343 14,569,242

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of share-based compensation expense	Share-based compensation expense in the following expense categories in the condensed consolidated statements of operations and comprehensive loss was as follows for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 General and administrative $ 670 $ 381 $ 1,206 $ 738 Sales and marketing 193 64 325 123 Research and development 244 93 418 184 Cost of revenues 46 27 87 53 Total share-based compensation $ 1,152 $ 565 $ 2,037 $ 1,098
Schedule of fair value of stock options and stock appreciation rights weighted average assumptions	The grant date fair value of stock options and stock appreciation rights was estimated using a Black-Scholes option pricing model with the following weighted average assumptions: Six Months Ended June 30, 2024 2023 Expected term (in years) 5.9 5.9 Expected volatility 61.8 % 54.4 % Risk-free rate 4.4 % 1.9 % Dividend rate — —
Schedule of stock options and stock appreciate rights activity	The following table summarizes stock option and SARs activity for the six months ended June 30, 2024: Number of Weighted- Weighted- Outstanding at December 31, 2023 9,342,589 $ 1.94 7.2 Granted 169,550 $ 3.92 Exercised (278,808) $ 0.88 Forfeited and expired (97,273) $ 3.59 Outstanding at June 30, 2024 9,136,058 $ 2.00 6.7 Exercisable at June 30, 2024 6,486,698 $ 1.74 6.2 Vested and expected to vest at June 30, 2024 9,136,058 $ 2.00 6.7
Schedule of restricted stock units and stock bonus awards activity	The following table summarizes RSU activity for the six months ended June 30, 2024: Number of Weighted Outstanding at December 31, 2023 303,688 $ 4.91 Granted 1,906,800 $ 3.94 Vested (111,783) $ 3.91 Forfeited and expired (29,687) $ 4.39 Outstanding at June 30, 2024 2,069,018 $ 4.08
Schedule of options vesting information	These options vest based on the CEO’s continued service in addition the Company's stock price reaching the following thresholds for a minimum of 20 out of 30 trading days before the option expiration dates: Tranche Number of Option Shares Stock Price Threshold Option Expiration 1 317,688 $9.00 March 3, 2031 2 46,273 $9.00 March 21, 2031 3 363,961 $13.50 March 21, 2031 Total 727,922

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of purchase commitment amounts and periods	The purchase commitment over the five-year period is $5.3 million and includes three commitment periods with the following commitment amounts: Commitment Period Commitment Period Commitment Amount 1 June 2024 to May 2026 $1,740 2 June 2026 to May 2028 2,265 3 June 2028 to May 2029 1,311 Total commitment $5,316

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of financial instruments measured at fair value	The following tables present information about our financial instruments that have been measured at fair value as of June 30, 2024 and December 31, 2023: June 30, (Level 1) (Level 2) (Level 3) Financial Assets Money market funds $ 25,339 $ 25,339 $ — $ — Total $ 25,339 $ 25,339 $ — $ — Financial Liabilities Loan payable $ 20,540 $ — $ — $ 20,540 Total $ 20,540 $ — $ — $ 20,540 December 31, (Level 1) (Level 2) (Level 3) Financial Assets Money market funds $ 43,104 $ 43,104 $ — $ — Total $ 43,104 $ 43,104 $ — $ — Financial Liabilities Loan payable $ 20,303 $ — $ — $ 20,303 Total $ 20,303 $ — $ — $ 20,303

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details)	1 Months Ended		6 Months Ended
	Nov. 30, 2023 USD ($) shares	Apr. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) country	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Class of Warrant or Right [Line Items]
Number of worldwide office locations | country			3
Common stock, issued, net proceeds	$ 26,300,000	$ 11,800,000	$ 0	$ 11,845,000
Direct financing costs	$ 2,500,000	$ 191,000
Issuance of common stock and warrants, net of issuance costs (in shares) | shares	7,187,500
Cash and cash equivalents			28,220,000	$ 24,551,000	$ 46,217,000
Incremental capital (up to)			5,000,000
Accumulated deficit			$ 159,911,000		$ 144,962,000
Pre-funded Warrants, Securities Purchase Agreement | Redmile and HINSIGHT-AUGX HOLDINGS, LLC | Maximum
Class of Warrant or Right [Line Items]
Warrants to purchase shares (in shares) | shares		4,375,273
Warrant One April 2023
Class of Warrant or Right [Line Items]
Exercise price per warrant (in dollars per share) | $ / shares		$ 0.0001
Breakeven Warrants, Securities Purchase Agreement | Redmile and HINSIGHT-AUGX HOLDINGS, LLC
Class of Warrant or Right [Line Items]
Exercise price per warrant (in dollars per share) | $ / shares		$ 1.75
Breakeven Warrants, Securities Purchase Agreement | Redmile and HINSIGHT-AUGX HOLDINGS, LLC | Maximum
Class of Warrant or Right [Line Items]
Warrants to purchase shares (in shares) | shares		1,875,069
Securities Purchase Agreement Offering | Redmile and HINSIGHT-AUGX HOLDINGS, LLC
Class of Warrant or Right [Line Items]
Sale of stock, number of shares issued (in shares) | shares		3,125,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Accounting Policies [Abstract]
Government grant income	$ 431	$ 78	$ 431	$ 78
Advertising expenses	$ 319	$ 210	$ 583	$ 428

Revenue, Accounts Receivable _3

Revenue, Accounts Receivable and Significant Customers - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Revenue From Contract With Customer, Accounts Receivable, And Concentration Risk [Line Items]
Revenue contracts, initial term			1 year
Sales commissions, amortization	$ 171	$ 215	$ 308	$ 372
Sales commissions, unamortized, current	441		441		$ 494
Sales commissions, unamortized, noncurrent	$ 103		$ 103		$ 153
Minimum
Revenue From Contract With Customer, Accounts Receivable, And Concentration Risk [Line Items]
Sales commissions, amortization period	12 months		12 months
Maximum
Revenue From Contract With Customer, Accounts Receivable, And Concentration Risk [Line Items]
Sales commissions, amortization period	24 months		24 months

Revenue, Accounts Receivable _4

Revenue, Accounts Receivable and Significant Customers - Changes in contract liability (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Contract With Customer, Liability [Roll Forward]
Balance, beginning of period	$ 8,963	$ 7,254
Deferral of revenue	23,687	42,846
Recognition of unearned revenue	(23,748)	(41,137)
Balance, end of period	$ 8,902	$ 8,963

Revenue, Accounts Receivable _5

Revenue, Accounts Receivable and Significant Customers - Concentration risk (Details) - Customer Concentration Risk	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Customer A | Percent of Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	30%	21%	30%	19%
Customer A | Percent of Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage			33%		35%
Customer B | Percent of Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	11%	14%	11%	14%
Customer C | Percent of Revenue
Concentration Risk [Line Items]
Concentration risk, percentage	10%	12%	10%	12%
Customer D | Percent of Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage					10%

Property and Equipment - Schedu

Property and Equipment - Schedule of property and equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total cost	$ 7,054	$ 7,230
Less: accumulated depreciation	(3,720)	(3,491)
Property and equipment, net	3,333	3,739
Computer hardware, software and equipment
Property, Plant and Equipment [Line Items]
Total cost	4,809	4,730
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total cost	915	716
Capitalized internal-use software costs
Property, Plant and Equipment [Line Items]
Total cost	712	698
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total cost	607	693
Construction in progress
Property, Plant and Equipment [Line Items]
Total cost	$ 10	$ 393

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 416	$ 262	$ 855	$ 541
Gain (loss) on disposal of leasehold improvements and equipment	$ 6	$ 0	$ (49)	$ 0

Accrued expenses and other cu_3

Accrued expenses and other current liabilities - Schedule of accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued compensation	$ 2,440	$ 3,860
Accrued professional fees	1,570	138
Accrued vendor partner liabilities	1,290	1,285
Accrued indirect taxes	336	393
Revenue refund reserve	199	198
Accrued interest payable	142	146
Accrued other	952	569
Total accrued expenses and other current liabilities	$ 6,929	$ 6,589

Debt - Narrative (Details)

Debt - Narrative (Details)			3 Months Ended		6 Months Ended		13 Months Ended
	Jun. 12, 2023	May 04, 2022 USD ($) tranche $ / shares shares	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 13, 2023 $ / shares shares	Jun. 26, 2024 USD ($) $ / shares	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Amortized discount of interest expense			$ 151,000	$ 126,000	$ 300,000	$ 225,000
SVB Loan Agreement | Warrants Issued May 2022 | Silicon Valley Bank
Debt Instrument [Line Items]
Exercise price per warrant (in dollars per share) | $ / shares		$ 2.38
SVB Loan Agreement | Maximum | Warrants Issued May 2022 | Silicon Valley Bank
Debt Instrument [Line Items]
Warrants to purchase shares (in shares) | shares		48,295
SVB Loan Agreement, Amendment One | Warrants Issued May 2022 and Warrants Issued June 2023 | Silicon Valley Bank
Debt Instrument [Line Items]
Warrants, term							7 years
SVB Loan Agreement, Amendment One | Warrants Issued June 2023 | Silicon Valley Bank
Debt Instrument [Line Items]
Exercise price per warrant (in dollars per share) | $ / shares							$ 3.01
SVB Loan Agreement, Amendment One | Maximum | Warrants Issued June 2023 | Silicon Valley Bank
Debt Instrument [Line Items]
Warrants to purchase shares (in shares) | shares							190,330
SVB Loan Agreement, Amendment Two | Silicon Valley Bank | Asset Pledged as Collateral
Debt Instrument [Line Items]
Cash collateral account								$ 5,000,000
SVB Loan Agreement, Amendment Two | Warrants Issued June 2023 | Silicon Valley Bank
Debt Instrument [Line Items]
Exercise price per warrant (in dollars per share) | $ / shares								$ 1.09
Revolving Credit Facility | SVB Loan Agreement | Line of Credit
Debt Instrument [Line Items]
Covenant, minimum revenue requirements, trailing measurement period		3 months
Covenant, minimum cash and cash equivalents requirement, minimum net cash proceeds from sale of equity		$ 10,000,000
Amount borrowed			$ 0		$ 0				$ 0
Revolving Credit Facility | SVB Loan Agreement | Line of Credit | Prior to Tranche B Advance
Debt Instrument [Line Items]
Covenant, minimum cash and cash equivalents		25,000,000
Revolving Credit Facility | SVB Loan Agreement | Line of Credit | Following Tranche B Advance
Debt Instrument [Line Items]
Covenant, minimum cash and cash equivalents		30,000,000
Revolving Credit Facility | SVB Loan Agreement | Line of Credit | Borrowing Component One
Debt Instrument [Line Items]
Aggregate principal amount available (up to)		$ 5,000,000
Revolving Credit Facility | SVB Loan Agreement | Line of Credit | Borrowing Component Two
Debt Instrument [Line Items]
Debt covenant, percent of eligible accounts		80%
Secured Debt | SVB Loan Agreement | Line of Credit
Debt Instrument [Line Items]
Number of tranches available | tranche		2
Covenant, end of term payment		$ 1,200,000
Secured Debt | SVB Loan Agreement | Line of Credit | Tranche A
Debt Instrument [Line Items]
Aggregate principal amount available (up to)		15,000,000
Secured Debt | SVB Loan Agreement | Line of Credit | Tranche B
Debt Instrument [Line Items]
Aggregate principal amount available (up to)		$ 5,000,000
Secured Debt | SVB Loan Agreement, Amendment One | Line of Credit | Prepayment Fee Component One
Debt Instrument [Line Items]
Prepayment fee, percent of outstanding principal	2.50%
Secured Debt | SVB Loan Agreement, Amendment One | Line of Credit | Prepayment Fee Component Two
Debt Instrument [Line Items]
Prepayment fee, percent of outstanding principal	1.50%
Secured Debt | SVB Loan Agreement, Amendment One | Line of Credit | Prepayment Fee Component Three
Debt Instrument [Line Items]
Prepayment fee, percent of outstanding principal	0.50%
Secured Debt | SVB Loan Agreement, Amendment One | Line of Credit | Interest Rate Component One
Debt Instrument [Line Items]
Interest rate	6%
Interest rate	0%
Secured Debt | SVB Loan Agreement, Amendment One | Line of Credit | Interest Rate Component Two
Debt Instrument [Line Items]
Interest rate	6.50%
Interest rate	0.50%

Debt - Schedule of future minim

Debt - Schedule of future minimum payments under the loan agreement (Details) - Revolving Credit Facility - SVB Loan Agreement - Secured Debt $ in Thousands	Jun. 30, 2024 USD ($)
Debt Instrument [Line Items]
2024 (6 months remaining)	$ 0
2025	10,000
2026	11,225
Total long-term debt, gross	21,225
Less: unamortized debt discount	(685)
Loan payable net of discount	20,540
Less: current portion	(5,000)
Loan payable, non-current portion	$ 15,540

Leases - Schedule of operating

Leases - Schedule of operating lease cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Operating lease cost	$ 406	$ 336	$ 816	$ 546
Short-term lease cost	15	91	68	175
Total lease cost	$ 421	$ 427	$ 884	$ 721

Leases - Schedule of other leas

Leases - Schedule of other lease information (Details)	Jun. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Weighted-average remaining lease term (in years)	3 years 6 months	4 years
Weighted-average discount rate	8.30%	8.30%

Leases - Schedule of lease matu

Leases - Schedule of lease maturities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Leases [Abstract]
2024 (remaining six months)	$ 686
2025	1,636
2026	1,695
2027	1,021
2028	459
2029	10
Total	5,507
Less: imputed interest	(773)
Operating lease liability	4,734
Less: Operating lease liability, current portion	1,432	$ 1,494
Operating lease liability, net of current portion	$ 3,303	$ 4,049

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of warrants outstanding to acquire shares of its common stock (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Class of Warrant or Right [Line Items]
Shares Issuable upon Exercise of Warrants (in shares)	8,478,540
Warrants, Expire October 25, 2024
Class of Warrant or Right [Line Items]
Expiration Date	Oct. 25, 2024
Shares Issuable upon Exercise of Warrants (in shares)	346,500
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 3
Warrants, Expire June 11, 2025
Class of Warrant or Right [Line Items]
Expiration Date	Jun. 11, 2025
Shares Issuable upon Exercise of Warrants (in shares)	234
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 96.24
Warrants, Expire November 13, 2025
Class of Warrant or Right [Line Items]
Expiration Date	Nov. 13, 2025
Shares Issuable upon Exercise of Warrants (in shares)	84,964
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 3
Warrants, Expire July 28, 2027
Class of Warrant or Right [Line Items]
Expiration Date	Jul. 28, 2027
Shares Issuable upon Exercise of Warrants (in shares)	91
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 106.17
Warrants, Expire August 28, 2028
Class of Warrant or Right [Line Items]
Expiration Date	Aug. 28, 2028
Shares Issuable upon Exercise of Warrants (in shares)	1,052
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 39.76
Warrants, Expire May 4, 2029
Class of Warrant or Right [Line Items]
Expiration Date	May 04, 2029
Shares Issuable upon Exercise of Warrants (in shares)	48,295
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 4
Warrants, Expire September 2, 2029
Class of Warrant or Right [Line Items]
Expiration Date	Sep. 02, 2029
Shares Issuable upon Exercise of Warrants (in shares)	1,556,732
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 2.88
Warrants, Expire April 19, 2030
Class of Warrant or Right [Line Items]
Expiration Date	Apr. 19, 2030
Shares Issuable upon Exercise of Warrants (in shares)	1,875,069
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 1.75
Warrants, Expire June 13, 2030
Class of Warrant or Right [Line Items]
Expiration Date	Jun. 13, 2030
Shares Issuable upon Exercise of Warrants (in shares)	190,330
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 1.09
Warrants, Perpetual Expiration
Class of Warrant or Right [Line Items]
Shares Issuable upon Exercise of Warrants (in shares)	4,375,273
Exercise Price Per Warrant (in dollars per share) | $ / shares	$ 0.0001

Loss Per Share - Schedule of ba

Loss Per Share - Schedule of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator
Net Loss	$ (8,450)	$ (6,499)	$ (5,033)	$ (5,239)	$ (14,949)	$ (10,272)
Denominator
Weighted average shares, basic (in shares)	53,387,349		43,607,984		53,223,008	40,566,425
Weighted average shares, diluted (in shares)	53,387,349		43,607,984		53,223,008	40,566,425
Net loss per share, basic (in dollars per share)	$ (0.16)		$ (0.12)		$ (0.28)	$ (0.25)
Net loss per share, diluted (in dollars per share)	$ (0.16)		$ (0.12)		$ (0.28)	$ (0.25)

Loss Per Share - Schedule of an

Loss Per Share - Schedule of anti-dilutive securities (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total excluded from computation of diluted weighted-average shares (in shares)	15,308,343	14,569,242
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total excluded from computation of diluted weighted-average shares (in shares)	4,103,267	4,743,466
Stock options and stock appreciation rights
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total excluded from computation of diluted weighted-average shares (in shares)	9,136,058	9,562,621
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total excluded from computation of diluted weighted-average shares (in shares)	2,069,018	263,155

Equity Incentive Plan - Narrati

Equity Incentive Plan - Narrative (Details) - 2020 Plan $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Mar. 31, 2021 trading_day $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares reserved for issuance, annual increase criteria, total number of common shares outstanding, percent (lesser of)		5%
Shares available for grant (in shares) | shares		812,032
Options exercised, intrinsic value		$ 863
Options outstanding, intrinsic value		400
Options exercisable, intrinsic value		$ 400
Chief Executive Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost, recognition period		1 month 6 days
Granted (in shares) | shares	727,922
Exercise price (in dollars per share) | $ / shares	$ 3
Options, minimum number of trading days after becoming listed, vesting criteria numerator | trading_day	20
Options, minimum number of trading days after becoming listed, vesting criteria denominator | trading_day	30
Unamortized share-based compensation expense		$ 6
Stock options and stock appreciation rights
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Contractual life (up to)		10 years
Unrecognized compensation cost		$ 2,500
Unrecognized compensation cost, recognition period		2 years 2 months 12 days
Stock options and stock appreciation rights | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period (not greater than)		4 years
Stock Appreciation Rights (SARs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant date fair value, non-options (in dollars per share) | $ / shares		$ 2.33	$ 1.13
Granted (in dollars per share) | $ / shares		$ 2.33	$ 1.13
Restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost, recognition period		3 years 7 months 6 days
Intrinsic value, outstanding		$ 1,800
Non-option, unrecognized compensation cost		$ 7,900

Equity Incentive Plan - Schedul

Equity Incentive Plan - Schedule of share-based compensation expense (Details) - 2020 Plan - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation	$ 1,152	$ 565	$ 2,037	$ 1,098
General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation	670	381	1,206	738
Sales and marketing
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation	193	64	325	123
Research and development
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation	244	93	418	184
Cost of revenues
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation	$ 46	$ 27	$ 87	$ 53

Equity Incentive Plan - Sched_2

Equity Incentive Plan - Schedule of fair value of option grants weighted average assumptions (Details) - 2020 Plan - Employee Stock Options and Stock Appreciation Rights (SARs)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (in years)	5 years 10 months 24 days	5 years 10 months 24 days
Expected volatility	61.80%	54.40%
Risk-free rate	4.40%	1.90%
Dividend rate	0%	0%

Equity Incentive Plan - Stock o

Equity Incentive Plan - Stock options and stock appreciation rights activity (Details) - 2020 Plan - Stock options and stock appreciation rights - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Number of Shares under Equity Plan
Outstanding, Beginning balance (in shares)	9,342,589
Granted (in shares)	169,550
Exercised (in share)	(278,808)
Forfeited and expired (in shares)	(97,273)
Outstanding, Ending balance (in share)	9,136,058	9,342,589
Exercisable (in shares)	6,486,698
Vested and expected to vest (in shares)	9,136,058
Weighted- Average Exercise Price per Option
Outstanding, Beginning balance (in dollars per share)	$ 1.94
Granted (in dollars per share)	3.92
Exercised (in dollars per share)	0.88
Forfeited and expired (in dollars per share)	3.59
Outstanding, Ending balance (in dollars per share)	2	$ 1.94
Exercisable (in dollars per share)	1.74
Vested and expected to vest (in dollars per share)	$ 2
Weighted- Average Remaining Contractual Life (in years)
Outstanding	6 years 8 months 12 days	7 years 2 months 12 days
Exercisable	6 years 2 months 12 days
Vested and expected to vest	6 years 8 months 12 days

Equity Incentive Plan - RSUs an

Equity Incentive Plan - RSUs and stock bonus award activity (Details) - RSUs and Stock Awards - 2020 Plan	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of Shares under Equity Plan
Outstanding, Beginning balance (in shares) | shares	303,688
Granted (in shares) | shares	1,906,800
Vested (in shares) | shares	(111,783)
Forfeited and expired (in shares) | shares	(29,687)
Outstanding, Ending balance (in shares) | shares	2,069,018
Weighted Average Grant Date Fair Value
Outstanding, Beginning balance (in dollars per share) | $ / shares	$ 4.91
Granted (in dollars per share) | $ / shares	3.94
Vested (in dollars per share) | $ / shares	3.91
Forfeited and expired (in dollars per share) | $ / shares	4.39
Outstanding, Ending balance (in dollars per share) | $ / shares	$ 4.08

Equity Incentive Plan - Sched_3

Equity Incentive Plan - Schedule of options vesting information (Details) - 2020 Plan - Chief Executive Officer	1 Months Ended
	Mar. 31, 2021 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Option Shares (in shares)	727,922
Tranche 1
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Option Shares (in shares)	317,688
Stock Price Threshold (in dollars per share) | $ / shares	$ 9
Tranche 2
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Option Shares (in shares)	46,273
Stock Price Threshold (in dollars per share) | $ / shares	$ 9
Tranche 3
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Option Shares (in shares)	363,961
Stock Price Threshold (in dollars per share) | $ / shares	$ 13.50

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution, percent of match			25%
Employer matching contribution, percent of employees' gross pay			4%
Service vesting period			1 year
Employment benefit plan, expense	$ 107	$ 77	$ 234	$ 201
Cash benefit eligibility, years of services completed			5 years
Gratuity fund liability	361		$ 361		$ 421
401(k) Plan
Defined Contribution Plan Disclosure [Line Items]
Employment benefit plan, expense	$ 67	$ 38	$ 126	$ 90

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - Cloud Computing Services $ in Thousands	1 Months Ended
	May 31, 2024 USD ($) commitment_period	Jun. 30, 2021	Jun. 30, 2024 USD ($)
Other Commitments [Line Items]
Purchase commitment, term	5 years	3 years
Total commitment	$ 5,316
Purchase commitment, number of commitment periods | commitment_period	3
Purchase commitment, amount satisfied			$ 56

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of commitment amounts by period (Details) $ in Thousands	1 Months Ended
	May 31, 2024 USD ($)
Cloud Computing Services
Long-Term Purchase Commitment [Line Items]
Total commitment	$ 5,316
Commitment Period 1
Long-Term Purchase Commitment [Line Items]
Total commitment	1,740
Commitment Period 2
Long-Term Purchase Commitment [Line Items]
Total commitment	2,265
Commitment Period 3
Long-Term Purchase Commitment [Line Items]
Total commitment	$ 1,311

Fair Value Measurements - Finan

Fair Value Measurements - Financial instruments carried at fair value (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Financial Assets
Total	$ 25,339	$ 43,104
Financial Liabilities
Loan payable	20,540	20,303
Total	20,540	20,303
(Level 1)
Financial Assets
Total	25,339	43,104
Financial Liabilities
Loan payable	0	0
Total	0	0
(Level 2)
Financial Assets
Total	0	0
Financial Liabilities
Loan payable	0	0
Total	0	0
(Level 3)
Financial Assets
Total	0	0
Financial Liabilities
Loan payable	20,540	20,303
Total	20,540	20,303
Money market funds
Financial Assets
Money market funds	25,339	43,104
Money market funds | (Level 1)
Financial Assets
Money market funds	25,339	43,104
Money market funds | (Level 2)
Financial Assets
Money market funds	0	0
Money market funds | (Level 3)
Financial Assets
Money market funds	$ 0	$ 0

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2015
Related Party Transaction [Line Items]
Owed to related party	$ 881		$ 881		$ 721
Related Party | Bangladesh
Related Party Transaction [Line Items]
Operating lease, rent expense	0	$ 101	70	$ 195
Owed to related party	$ 2		$ 2		$ 8
Related Party | Bangladesh Subsidiary | Bangladesh
Related Party Transaction [Line Items]
Operating lease term						10 years

Subsequent Event (Details)

Subsequent Event (Details) - $ / shares	Jul. 19, 2024	Jun. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
Common stock, par value (in dollars per share)		$ 0.0001	$ 0.0001
Subsequent Event
Subsequent Events [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001
Subsequent Event | Augmedix, Inc. | Commure, Inc.
Subsequent Events [Abstract]
Share price (in dollars per share)	$ 2.35